

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number
WO 01/19814 A2

(51) International Patent Classification⁷: C07D 333/24, A61K 31/381, 31/44, A61P 19/02, 29/00, C07D 333/16, 333/28, 409/10, 409/12, 333/34

(74) Agents: MURPHY, Kevin, P. et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).

(21) International Application Number: PCT/CA00/01059

(22) International Filing Date: 13 September 2000 (13.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/153,899 14 September 1999 (14.09.1999) US

(71) Applicant (for all designated States except US): MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LACOMBE, Patrick [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). LABELLE, Marc [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). RUEL, Rejean [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

WO 01/19814 A2



(57) Abstract: This invention encompasses the novel compounds of formula (A), which are useful in the treatment of prostaglandin mediated diseases, or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses certain pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases comprising the use of compounds of formula (A).

54

TITLE OF THE INVENTION

CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS
CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

5 BACKGROUND OF THE INVENTION

This invention relates to compounds and methods for treating prostaglandin mediated diseases, and certain pharmaceutical compositions thereof. The compounds of the invention are structurally different from NSAIDs and opiates, and are antagonists of the pain and inflammatory effects of E-type prostaglandins.


10 Two review articles describe the characterization and therapeutic relevance of the prostanoid receptors as well as the most commonly used selective agonists and antagonists: *Eicosanoids: From Biotechnology to Therapeutic Applications*, Folco, Samuelsson, Maclouf, and Velo eds, Plenum Press, New York, 1996, chap. 14, 137-154 and *Journal of Lipid Mediators and Cell Signalling*, 1996, 14, 83-87. An article from *The British Journal of Pharmacology* (1994, 112, 735-740) suggests that Prostaglandin E₂ (PGE₂) exerts allodynia through the EP₁ receptor subtype and hyperalgesia through EP₂ and EP₃ receptors in the mouse spinal cord.

15 Thus, selective prostaglandin ligands, agonists or antagonists, depending on which prostaglandin E receptor subtype is being considered, have anti-
20 inflammatory, antipyretic and analgesic properties similar to a conventional non-steroidal anti-inflammatory drug, and in addition, inhibit hormone-induced uterine contractions and have anti-cancer effects. These compounds have a diminished ability to induce some of the mechanism-based side effects of NSAIDs which are indiscriminate cyclooxygenase inhibitors. In particular, the compounds have a
25 reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.

20 In *The American Physiological Society* (1994, 267, R289-R-294), studies suggest that PGE2-induced hyperthermia in the rat is mediated predominantly through the EP₁ receptor. World patent applications WO 96/06822 (March 7, 1996),
30 WO 96/11902 (April 25, 1996) and EP 752421-A1 (January 08, 1997) disclose compounds as being useful in the treatment of prostaglandin mediated diseases.

SUMMARY OF THE INVENTION

The present invention relates to compounds represented by formula A

**A**

5 as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein:

y and z are independently 0-2, such that $y + z = 2$;

R^a is selected from the group consisting of:

10 1) heteroaryl, wherein heteroaryl is selected from the group consisting of:

- a) furyl,
- b) diazinyl, triazinyl or tetrazinyl,
- c) imidazolyl,
- 15 d) isoxazolyl,
- e) isothiazolyl,
- f) oxadiazolyl,
- g) oxazolyl,
- h) pyrazolyl,
- 20 i) pyrrolyl,
- j) thiadiazolyl,
- k) thiazolyl
- l) thienyl

- m) triazolyl and
- n) tetrazolyl,

said heteroaryl group being optionally substituted with one to three substituents selected from R¹¹ and C₁₋₄alkyl,

- 5 2) -COR⁶,
- 3) -NR⁷R⁸,
- 4) -SO₂R⁹,
- 5) hydroxy,
- 6) C₁₋₆alkoxy, optionally substituted with one to three

10 substituents selected from R¹¹, and

- 7) C₁₋₆alkyl, C₂₋₆alkenyl or C₃₋₆cycloalkyl, optionally

substituted with one to three substituents selected from R¹¹, and further substituted with 1-3 substituents selected from the group consisting of:

- 15 (a) -COR⁶
- (b) -NR⁷R⁸,
- (c) -SO₂R⁹,
- (d) hydroxy,
- (e) C₁₋₆alkoxy or haloC₁₋₆alkoxy, and
- (f) heteroaryl,

20 such that R^a is positioned on the phenyl ring to which it is bonded in a 1,3 or 1,4 relationship relative to the thienyl group represented in formula A;

each R¹, R², R³, R⁴ and R⁵ are independently selected from the group consisting of:

- 25 1) hydrogen,
- 2) halogen,
- 3) C₁₋₆alkyl,
- 4) C₁₋₆alkoxy,
- 5) C₁₋₆alkylthio,
- 6) nitro,

7) carboxy and
8) CN, wherein items (3)-(5) above are optionally substituted with one or more substituents independently selected from R11;

5 R6 is selected from the group consisting of hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy and NR⁷R⁸, wherein C1-6alkyl or C1-6alkoxy are optionally substituted with one or more substituents independently selected from R11;

R⁷ and R⁸ are independently selected from the group consisting of:

10 (1) hydrogen,
(2) hydroxy,
(3) SO₂R⁹
(4) C1-6alkyl,
(5) C1-6alkoxy,

15 (6) phenyl,
(7) naphthyl,
(8) furyl,
(9) thienyl and
(10) pyridyl, wherein items (4)-(5) above are optionally substituted with one or more substituents independently selected from R11, and items (6)-(10) above are optionally substituted with one or more substituents independently selected from R11 or C1-4alkyl,

20 R⁹ is selected from the group consisting of

25 (1) hydroxy,
(2) N(R¹⁰)₂,
(3) C1-6alkyl, optionally substituted with one or more substituents independently selected from R11,
(4) phenyl,

30 (5) naphthyl,
(6) furyl,
(7) thienyl and
(8) pyridyl, wherein items (4)-(8) above are optionally substituted with one or more substituents independently selected from R11 or C1-4alkyl;


R¹⁰ is hydrogen or C₁-6alkyl; and

R¹¹ is the group consisting of halogen, hydroxy, C₁-3alkoxy, nitro, N(R¹⁰)₂ and pyridyl.

5 The invention also encompasses pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases.

DETAILED DESCRIPTION OF THE INVENTION

In one aspect of the invention, the invention encompasses
10 compounds represented by formula A:



A

as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein:

15 y and z are independently 0-2, such that y + z = 2;

R^a is selected from the group consisting of:

1) heteroaryl, wherein heteroaryl is selected from the group consisting of:
20

- a) furyl,
- b) diazinyl, triazinyl or tetrazinyl,
- c) imidazolyl,
- d) isoxazolyl,
- e) isothiazolyl,

- f) oxadiazolyl,
- g) oxazolyl,
- h) pyrazolyl,
- i) pyrrolyl,
- 5 j) thiadiazolyl,
- k) thiazolyl
- l) thienyl
- m) triazolyl and
- n) tetrazolyl,

10 said heteroaryl group being optionally substituted with one to three substituents selected from R¹¹ and C₁₋₄alkyl,

- 2) -COR⁶,
- 3) -NR⁷R⁸,
- 4) -SO₂R⁹,
- 15 5) hydroxy,
- 6) C₁₋₆alkoxy, optionally substituted with 1-3 substituents selected from R¹¹, and

7) C₁₋₆alkyl, C₂₋₆alkenyl or C₃₋₆cycloalkyl, optionally substituted with 1-3 substituents selected from R¹¹, and further substituted with 1-3 substituents selected from the group consisting of:

- (a) -COR⁶
- (b) -NR⁷R⁸,
- (c) -SO₂R⁹,
- (d) hydroxy,
- 25 (e) C₁₋₆alkoxy or haloC₁₋₆alkoxy, and
- (f) heteroaryl,

such that R^a is positioned on the phenyl ring to which it is bonded in a 1,3 or 1,4 relationship relative to the thienyl group represented in formula A;

R¹, R², R³, R⁴ and R⁵ are independently selected from the group consisting of:

- 1) hydrogen,
- 2) halogen,
- 3) C₁-6alkyl,
- 5 4) C₁-6alkoxy,
- 5) C₁-6alkylthio,
- 6) nitro,
- 7) carboxy and
- 8) CN, wherein items (3)-(5) above are optionally substituted with
10 one or more substituents independently selected from R¹¹;

R⁶ is selected from the group consisting of hydrogen, hydroxy, C₁-6alkyl, C₁-6alkoxy and NR⁷R⁸, wherein C₁-6alkyl or C₁-6alkoxy are optionally substituted with one or more substituents independently selected from R¹¹;

15

R⁷ and R⁸ are independently selected from the group consisting of:

- (1) hydrogen,
- (2) hydroxy,
- (3) SO₂R⁹
- 20 (4) C₁-6alkyl,
- (5) C₁-6alkoxy,
- (6) phenyl,
- (7) naphthyl,
- (8) furyl,
- 25 (9) thienyl and
- (10) pyridyl, wherein items (4)-(5) above are optionally substituted with one or more substituents independently selected from R¹¹, and items (6)-(10) above are optionally substituted with one or more substituents independently selected from R¹¹ or C₁-4alkyl,

30

R⁹ is selected from the group consisting of

- (1) hydroxy,
- (2) N(R¹⁰)₂,

(3) C₁-6alkyl, optionally substituted with one or more substituents independently selected from R¹¹,

(4) phenyl,

(5) naphthyl,

5 (6) furyl,

(7) thiényl and

(8) pyridyl, wherein items (4)-(8) above are optionally substituted with one or more substituents independently selected from R¹¹ or C₁-4alkyl;

10 R¹⁰ is hydrogen or C₁-6alkyl; and


R¹¹ is the group consisting of halogen, hydroxy, C₁-3alkoxy, nitro, N(R¹⁰)₂ and pyridyl.

An embodiment of the invention that is of particular interest relates to

15 compounds of formula A wherein R^a is selected from the group consisting of: heteroaryl, as originally defined, COR⁶, wherein R⁶ is as originally defined, C₁-6 alkyl and C₂-6 alkenyl, optionally substituted as originally defined, and SO₂R⁹ with R⁹ as originally defined. Within this subset, all other variables are as originally defined.


20 More particularly, an embodiment of the invention that is of interest relates to a compound of formula A wherein R^a is selected from the group consisting of:

(1)






25

(2)





(3)









5




10




15



(12)




(13)




5

(14)




(15)




10


(16)




(17)




(18)



(19)



(20)



5

Within this embodiment of the invention, all other variables are as originally defined.

Another embodiment of the invention that is of particular interest relates to compounds of formula A wherein 1-3 of R¹ and R² are selected from the group consisting of halo, C₁-4 alkyl, C₁-4 alkoxy, C₁-4 alkylthio and NO₂. Within 10 this subset, all other variables are as originally defined.

Another embodiment of the invention that is of particular interest relates to compounds of formula A wherein each R⁴ and R⁵ independently represents a member selected from the group consisting of: H, halo, C₁-6 alkyl and C₁-6 alkoxy, said alkyl and alkoxy groups being optionally substituted as originally defined.

15 Within this subset, all other variables are as originally defined.

Another embodiment of the invention that is of particular interest relates to compounds of formula A wherein each R³ independently represents a member selected from the group consisting of: H and halo. Within this subset, all other variables are as originally defined.

20 Another embodiment of the invention that is of particular interest relates to compounds of formula A wherein one of y and z represents 0 and the other represents 2. Within this subset, all other variables are as originally defined.

An embodiment of the invention that is of more particular interest relates to compounds of formula A wherein R^a is selected from the group consisting 25 of: heteroaryl, as originally defined, COR⁶, wherein R⁶ is as originally defined, C₁-6 alkyl and C₂-6 alkenyl, optionally substituted as originally defined, and SO₂R⁹ with R⁹ as originally defined;

1-3 of R¹ and R² are selected from the group consisting of halo, C 1-4 alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio and NO₂ ;

each R⁴ and R⁵ independently represents a member selected from the group consisting of: H, halo, C₁₋₆ alkyl and C₁₋₆ alkoxy, said alkyl and alkoxy

5 groups being optionally substituted as originally defined;


each R³ independently represents a member selected from the group consisting of: H and halo;

and one of y and z represents 0 and the other represents 2. Within this subset, all other variables are as originally defined.

10 Another embodiment of the invention that is of more particular interest relates to compounds of formula A wherein:


R^a is selected from the group consisting of:

(1)




15


(2)



(3)




(4)




20


(5)




(6)



(7)




(8)




5

(9)




(10)




10

(11)







(12)





15

(13)





10



1-3 of R¹ and R² are selected from the group consisting of halo, C 1-4 alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio and NO₂ ;
each R⁴ and R⁵ independently represents a member selected from the
5 group consisting of: H, halo, C₁₋₆ alkyl and C₁₋₆ alkoxy, said alkyl and alkoxy groups being optionally substituted as originally defined;
each R³ independently represents a member selected from the group consisting of: H and halo;
and one of y and z represents 0 and the other represents 2. Within this
10 subset, all other variables are as originally defined.

Exemplifying the invention are the following compounds:

- (a) 4-[3-[2-(Phenylmethoxy)phenyl]-2-thienyl]benzoic acid;
- (b) 4-[2-[2-(Phenylmethoxy)phenyl]-3-thienyl]benzoic acid;
- (c) 2-(4-[3-[2-(phenylmethoxy)phenyl]-2-thienyl]phenyl)acetic acid;
- (d) (4-[3-[2-(phenylmethoxy)phenyl]-2-thienyl]phenyl)methan-1-ol;
- (e) 2-(4-[3-[2-(phenylmethoxy)phenyl]-2-thienyl]phenyl)propan-2-ol;
- (f) 1-(4-[3-[2-(phenylmethoxy)phenyl]-2-thienyl]phenyl)ethan-1-ol;
- (g) 4-[5-bromo-3-[2-(phenylmethoxy)but-2-enyl]-2-thienyl]benzoic acid;
- (h) 4-[3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl]benzoic acid;
- (i) 3-[3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl]benzoic acid;
- (j) 2-chloro-5-[3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)]benzoic acid;
- (k) 2-[2-(3-(2H-1,2,3,4-tetraazol-5-yl)phenyl)(3-thienyl)]-4-chloro-1-(phenylmethoxy)benzene;
- (l) 5-[3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)]-2-methoxybenzoic acid;
- (m) 3-[3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)]-4-fluorobenzoic acid;

- (o) 3-{3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl}benzamide;
- (p) 2-(3-{3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl}phenyl)acetic acid;
- 5 (q) 4-{3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)}-2-methylbenzoic acid;
- (r) 4-(3-{2-[(2-chloro-4-fluorophenyl)methoxy]-5-nitrophenyl}-2-thienyl)benzoic acid;
- 10 (s) (4-{3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)}phenyl)-N-(3-pyridylmethyl)formamide;
- (t) [4-(3-{2-[(2-chloro-4-fluorophenyl)methoxy]-5-nitrophenyl}(2-thienyl))phenyl]-N-(3-pyridylmethyl)formamide;
- (u) (4-{3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)}phenyl)-N-(2-thienylsulfonyl)formamide;
- 15 (v) 4-(3-{2-[(2,4-difluorophenyl)methoxy]-5-chlorophenyl}(2-thienyl))-3-methylbenzoic acid;
- (w) 4-(3-{5-chloro-2-[(4-fluorophenyl)methoxy]phenyl}(2-thienyl))-3-methylbenzoic acid;
- (x) 4-{3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)}-3-methylbenzoic acid;
- 20 (y) 4-{4-[2-(phenylmethoxy)phenyl]-3-thienyl}benzoic acid;
- (z) (4-{4-[2-(phenylmethoxy)phenyl](3-thienyl)}phenyl)-N-(3-pyridylmethyl)formamide;
- (aa) 4-[3-(2-[(4-difluoromethoxy)phenyl]methoxy)-5-chlorophenyl](2-thienyl))-3-methylbenzoic acid;
- 25 (ab) 4-(3-{2-[(4-carboxyphenyl)methoxy]-5-chlorophenyl}-2-thienyl)benzoic acid;
- (ac) 3-(3-{2-[(4-carboxyphenyl)methoxy]-5-chlorophenyl}-2-thienyl)benzoic acid;
- (ad) 4-(3-{5-chloro-2-[(2-chloro-4-fluorophenyl)methoxy]phenyl}(2-thienyl))-3-methylbenzoic acid; and
- 30 (ae) [4-(3-{5-chloro-2-[(2-chloro-4-fluorophenyl)methoxy]phenyl}(2-thienyl))-3-methylphenyl]-N-(3-pyridylmethyl)formamide.

Another embodiment of the invention is a pharmaceutical composition comprising a compound of formula A in combination with a pharmaceutically acceptable carrier.

Another embodiment of the invention is a method of treating or preventing a prostaglandin mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula A in an amount which is effective for treating or preventing a prostaglandin mediated disease.

An embodiment of the invention is a method of treating or preventing a prostaglandin mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula A in an amount which is effective for treating or preventing a prostaglandin mediated disease, wherein the prostaglandin mediated disease is selected from the group consisting of:

- (1) pain, fever or inflammation associated with rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout, ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases;
- (2) cellular neoplastic transformations or metastatic tumor growth;
- (3) diabetic retinopathy and tumor angiogenesis;
- (4) prostanoid-induced smooth muscle contraction associated with dysmenorrhea, premature labor, asthma or eosinophil related disorders;
- (5) Alzheimer's disease;
- (6) glaucoma;
- (7) bone loss;
- (8) osteoporosis;
- (9) promotion of bone formation;
- (10) Paget's disease;
- (11) cytoprotection in peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or other gastrointestinal lesions;
- (12) GI bleeding and patients undergoing chemotherapy;
- (13) coagulation disorders selected from hypoprothrombinemia, haemophilia and other bleeding problems;
- (14) kidney disease;

- (15) thrombosis;
- (16) occlusive vascular disease;
- (17) presurgery; and
- (18) anti-coagulation.

5 Another embodiment of the invention is a method of treating or preventing a prostaglandin mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula A in an amount which is effective for treating or preventing a prostaglandin mediated disease, wherein the prostaglandin mediated disease is selected from the group consisting of: pain, 10 fever or inflammation associated with rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation 15 and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases;.

 Another embodiment of the invention is a method of treating or preventing a prostaglandin mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula A in an amount 20 which is effective for treating or preventing a prostaglandin mediated disease, wherein the prostaglandin mediated disease is pain, fever or inflammation associated with dysmenorrhea.

 Another embodiment of the invention is a method of treating or preventing a prostaglandin mediated disease comprising administering to a 25 mammalian patient in need of such treatment a compound of formula A in an amount which is effective for treating or preventing a prostaglandin mediated disease, wherein the compound is co-administered with one or more other agents or ingredients.

 Another embodiment of the invention is a method of treating or preventing a prostaglandin mediated disease comprising administering to a 30 mammalian patient in need of such treatment a compound of formula A in an amount which is effective for treating or preventing a prostaglandin mediated disease, wherein the compound is co-administered with another agent or ingredient selected from the group consisting of:

- (1) an analgesic selected from acetaminophen, phenacetin, aspirin, 35 and a narcotic;

(2) a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug or a conventional nonsteroidal anti-inflammatory drug;

(3) caffeine;

(4) an H₂-antagonist;

5 (5) aluminum or magnesium hydroxide;

(6) simethicone;

(7) a decongestant selected from phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine;

10 (8) an antiitussive selected from codeine, hydrocodone, caramiphen, carbetapentane and dextramethorphan;

(9) another prostaglandin ligand selected from misoprostol, enprostil, rioprostil, ornoprostol and rosaprostol; a diuretic; and

(10) a sedating or non-sedating antihistamine.

15 Examples of COX-2 inhibitors are disclosed in U.S. Patent Nos. 5,474,995; 5,633,272; and 5,466,823; and in WO 96/25405, WO 97/38986, WO 98/03484, WO 97/14691, and WO 95/0051.

Another embodiment of the invention is a method of treating or preventing a prostaglandin mediated disease comprising administering to a 20 mammalian patient in need of such treatment a compound of formula A in an amount which is effective for treating or preventing a prostaglandin mediated disease, wherein the compound is co-administered with a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug or a conventional nonsteroidal anti-inflammatory drug.

Another embodiment of the invention is a method of treating or 25 preventing a prostaglandin mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula A in an amount which is effective for treating or preventing a prostaglandin mediated disease, wherein the compound is co-administered with a conventional nonsteroidal anti-inflammatory drug selected from the group consisting of: aspirin, ibuprofen, naproxen, and 30 ketoprofen.

Another embodiment of the invention is a method of treating or preventing a prostaglandin mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula A in an amount which is effective for treating or preventing a prostaglandin mediated disease, wherein

the compound is co-administered with a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug selected from rofecoxib and celecoxib.

The invention is described using the following definitions unless otherwise indicated.

5 The term "halogen" or "halo" includes F, Cl, Br, and I.

The term "alkyl" means linear, branched or cyclic structures and combinations thereof, having the indicated number of carbon atoms. Thus, for example, C₁-6alkyl includes methyl, ethyl, propyl, 2-propyl, s- and t-butyl, butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

10 "Alkoxy" means alkoxy groups of a straight, branched or cyclic configuration having the indicated number of carbon atoms. C₁-6alkoxy, for example, includes methoxy, ethoxy, propoxy, isopropoxy, and the like.

"Alkylthio" means alkylthio groups having the indicated number of carbon atoms of a straight, branched or cyclic configuration. C₁-6alkylthio, for example, includes methylthio, propylthio, isopropylthio, etc. By way of illustration, the propylthio group signifies -SCH₂CH₂CH₃.

15 "Haloalkyl" means an alkyl group, including linear, branched or cyclic structures, of the indicated number of carbon atoms in which one or more hydrogen atoms have been replaced by halogen atoms, with up to complete substitution of all 20 hydrogen atoms with halo groups. C₁-6haloalkyl, for example, includes -CF₃, -CF₂CF₃ and the like.

25 "Haloalkoxy" means an alkoxy group, including linear, branched or cyclic structures, of the indicated number of carbon atoms in which one or more hydrogen atoms have been replaced by halogen atoms, with up to complete substitution of all hydrogen atoms with halo groups. C₁-6haloalkoxy, for example, includes -OCF₃, -OCF₂CF₃ and the like.

30 "Alkenyl" means linear or branched structures and combinations thereof, of the indicated number of carbon atoms, having at least one carbon-to-carbon double bond, wherein hydrogen may be replaced by an additional carbon-to-carbon double bond. C₂-6alkenyl, for example, includes ethenyl, propenyl, 1-methylethenyl, butenyl and the like.

For purposes of this specification, the following abbreviations have the indicated meanings:

35 BOC = t-butyloxycarbonyl
 CBZ = carbobenzoxy

	DCC	=	1,3-dicyclohexylcarbodiimide
	DIBAL	=	diisobutyl aluminum hydride
	DIEA	=	N,N-diisopropylethylamine
	DMAP	=	4-(dimethylamino)pyridine
5	EDCI	=	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
	EDTA	=	ethylenediaminetetraacetic acid, tetrasodium salt hydrate
	FAB	=	fast atom bombardment
10	FMOC	=	9-fluorenylmethoxycarbonyl
	HMPA	=	hexamethylphosphoramide
	HATU	=	O-(7-Azabenzotriazol-1-yl)N,N,N',N'-tetramethyluronium hexafluorophosphate
	HOBr	=	1-hydroxybenzotriazole
15	HRMS	=	high resolution mass spectrometry
	ICBF	=	isobutyl chloroformate
	KHMDS	=	potassium hexamethyldisilazane
	LDA	=	lithium diisopropylamide
	MCPBA	=	metachloroperbenzoic acid
20	Ms	=	methanesulfonyl = mesyl
	MsO	=	methanefulfonate = mesylate
	NBS	=	N-bromosuccinimide
	NMM	=	4-methylmorpholine
	PCC	=	pyridinium chlorochromate
25	PDC	=	pyridinium dichromate
	Ph	=	phenyl
	PPTS	=	pyridinium p-toluene sulfonate
	pTSA	=	p-toluene sulfonic acid
	r.t.	=	room temperature
30	rac.	=	racemic
	TfO	=	trifluoromethanesulfonate = triflate
	TLC	=	thin layer chromatography

Alkyl group abbreviations

35	Me	=	methyl
----	----	---	--------

	Et	=	ethyl
	n-Pr	=	normal propyl
	i-Pr	=	isopropyl
	n-Bu	=	normal butyl
5	i-Bu	=	isobutyl
	s-Bu	=	secondary butyl
	t-Bu	=	tertiary butyl

Unless otherwise specified, when a nitrogen atom appears in a structure, hydrogen atoms are implied to satisfy the valence requirement.

10 The pharmaceutical compositions of the present invention comprise a compound of formula A as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic
15 bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganese, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary,
20 secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine,
25 isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and
30 organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric,
35 sulfuric, and tartaric acids.

It will be understood that in the discussion of methods of treatment which follows, references to the compounds of formula A are meant to also include the pharmaceutically acceptable salts.

The magnitude of prophylactic or therapeutic dose of a compound of formula A will, of course, vary with the nature and the severity of the condition to be treated and with the particular compound of formula A and its route of administration. It will also vary according to a variety of factors including the age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination and response of the individual patient. In general, the daily dose from about 0.001 mg to 10 mg per kg body weight of a mammal, preferably about 0.01 mg to about 10 mg per kg. On the other hand, it may be necessary to use dosages outside these limits in some cases.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from about 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 2 g of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

For the treatment of any of the above mentioned diseases and conditions, the compound of formula A may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting

of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be
5 for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay
10 disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
15 Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid
20 paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum
25 tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial
30 esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, one

or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

10 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.

15 The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for 20 example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

25 Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which 30 have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene 35 glycols may also be used. In addition, sterile, fixed oils are conventionally employed

as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Compounds of formula A may also be administered in the form of
5 suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ambient temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, gels, solutions or suspensions, etc.,
10 containing the compound of formula A are employed. (For purposes of this application, topical application shall include mouth washes and gargles.) Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.

The ability of the compounds of formula A to interact with
15 prostaglandin receptors makes them useful for preventing or reversing undesirable symptoms caused by prostaglandins in a mammalian, especially human subject. This mimicking or antagonism of the actions of prostaglandins indicates that the compounds and pharmaceutical compositions thereof are useful to treat, prevent, or ameliorate in mammals and especially in humans: Pain, fever and inflammation of a
20 variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns
25 including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases. In addition, such a compound may inhibit cellular neoplastic transformations and metastatic tumor growth and hence can be used in the treatment of cancer. Compounds of formula A may also be of use in the treatment and/or prevention prostaglandin-mediated
30 proliferation disorders such as may occur in diabetic retinopathy and tumor angiogenesis. Compounds of formula A will also inhibit prostanoid-induced smooth muscle contraction by antagonizing contractile prostanoids or mimicking relaxing prostanoids and hence may be use in the treatment of dysmenorrhea, premature labor, asthma and eosinophil related disorders. It will also be of use in the treatment of
35 Alzheimer's disease, the treatment of glaucoma, for the prevention of bone loss

(treatment of osteoporosis) and for the promotion of bone formation (treatment of fractures) and other bone diseases such as Paget's disease.

By virtue of its prostanoid or prostanoid antagonist activity, a compound of formula A will prove useful as an alternative to conventional non-steroidal anti-inflammatory drugs (NSAID'S) particularly where such non-steroidal anti-inflammatory drugs may be contraindicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems; kidney disease; thrombosis, occlusive vascular diseases; those prior to surgery or taking anti-coagulants. Compounds of formula A will also be useful as a cytoprotective agent for patients under chemotherapy.

Compounds of formula A will be useful as a partial or complete substitute for conventional antiinflammatory or analgesic compounds in preparations wherein they are presently co-administered with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for treating prostaglandin E2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of formula A as defined above and one or more ingredients such as another pain reliever including acetaminophen or phenacetin; a COX-2 selective inhibiting agent; a conventional NSAID; a potentiator including caffeine; an H2-antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; another prostaglandin ligand including misoprostol, enprostil, rioprostil, ornoprostol or rosaproston; a diuretic; a sedating or non-sedating antihistamine. In addition, the invention encompasses a method of treating prostaglandin E2 mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of the compound of formula A, optionally co-administered with one or more of such ingredients as listed immediately above.


METHODS OF SYNTHESIS


Compounds of the present invention can be prepared according to the following methods.

5 Preparation of common intermediates

As illustrated in Scheme 1, the thiophene derivative (**3**) is prepared by reacting 2-bromophenylbenzyl ether (**1**) with thiophene 3-boronic acid (**2**) under conditions such as palladium catalyzed Suzuki's cross coupling reaction. The thiophene derivative (**3**) can then be brominated selectively at the 2 position using reagents such as NBS in THF/H₂O (50:1). Subsequent Suzuki's cross coupling 10 reaction with the desired boronic acid (**5**) affords the desired benzoic acid derivative (**6**).


Scheme 1






In a similar fashion, the thiophene isomers (13) can be prepared as shown in Scheme 2 by submitting 3-bromothiophene compounds (7) under palladium catalyzed Suzuki's cross coupling with the desired boronic acid (8) to give the derivative (9), which is then brominated selectively at the 2 position using reagents such as NBS in THF/H₂O (50:1). Finally, palladium catalyzed Suzuki's cross coupling reaction between the bromo derivative (10) and the desired boronic acid (11) followed by basic hydrolysis of the ester lead to the desired product (13).

Scheme 2







5

The other thiophene isomer (**17**) is prepared via a multi-step sequence as shown in Scheme 3. 3,4-dibromothiophene (**14**) is reacted with the boronic acid (**8**) to yield the derivative (**15**), which is once submitted to palladium catalyzed

Suzuki's cross coupling reaction with the desired boronic acid (11) followed by basic hydrolysis to afford the desired material (17).

Scheme 3




REPRESENTATIVE COMPOUNDS


Table 1 illustrates compounds of formula A which are representative of the present invention.

TABLE 1


<u>COMPOUND</u>	<u>EXAMPLE</u>
	1
	2
	3

TABLE 1 (Continued)COMPOUNDEXAMPLE

4



5



6

TABLE 1 (Continued)







<u>COMPOUND</u>	<u>EXAMPLE</u>
	7
	8
	9

TABLE 1 (Continued)COMPOUNDEXAMPLE


10




11




12

TABLE 1 (Continued)COMPOUNDEXAMPLE


13




14




15

TABLE 1 (Continued)COMPOUNDEXAMPLE

16



17



18






TABLE 1 (Continued)COMPOUNDEXAMPLE

TABLE 1 (Continued)COMPOUNDEXAMPLE

22



23



25







TABLE 1 (Continued)COMPOUNDEXAMPLE


26




27

TABLE 1 (Continued)COMPOUNDEXAMPLE


28




29




30

TABLE 1 (Continued)COMPOUNDEXAMPLE

31




37




38

TABLE 1 (Continued)COMPOUNDEXAMPLE

39



40



41







TABLE 1 (Continued)COMPOUNDEXAMPLE


43




44

TABLE 1 (Continued)COMPOUNDEXAMPLE


45




46




47

TABLE 1 (Continued)COMPOUNDEXAMPLE


48




49




50

TABLE 1 (Continued)COMPOUNDEXAMPLE


52




53

TABLE 1 (Continued)COMPOUNDEXAMPLE


55




56




57

TABLE 1 (Continued)COMPOUNDEXAMPLE


58




59




60

TABLE 1 (Continued)COMPOUNDEXAMPLE


61




62




63

TABLE 1 (Continued)COMPOUNDEXAMPLE


64




65




66

TABLE 1 (Continued)COMPOUNDEXAMPLE


67




68




69

TABLE 1 (Continued)COMPOUNDEXAMPLE


70




71




76

TABLE 1 (Continued)COMPOUNDEXAMPLE


77




78




79

TABLE 1 (Continued)COMPOUNDEXAMPLE


80




81




82

TABLE 1 (Continued)COMPOUNDEXAMPLE

83




84




85

TABLE 1 (Continued)COMPOUNDEXAMPLE

86



87



88

ASSAYS FOR DETERMINING BIOLOGICAL ACTIVITY

The compounds of formula A can be tested using the following assays to demonstrate their prostanoid antagonist or agonist activity *in vitro* and *in vivo* and their selectivity. The prostaglandin receptors investigated are DP, EP₁, EP₂, EP₃,
5 EP₄, FP, IP and TP.

Stable expression of prostanoid receptors in the human embryonic kidney (HEK) 293(ebna) cell line

Prostanoid receptor cDNAs corresponding to full length coding sequences were subcloned into the appropriate sites of mammalian expression vectors and transfected into HEK 293(ebna) cells. HEK 293(ebna) cells expressing the individual cDNAs were grown under selection and individual colonies were isolated after 2-3 weeks of growth using the cloning ring method and subsequently expanded into clonal cell lines.
10

15 Prostanoid receptor binding assays

HEK 293(ebna) cells are maintained in culture, harvested and membranes are prepared by differential centrifugation, following lysis of the cells in the presence of protease inhibitors, for use in receptor binding assays. Prostanoid receptor binding assays are performed in 10 mM MES/KOH (pH 6.0) (EPs, FP and TP) or 10 mM HEPES/KOH (pH 7.4) (DP and IP), containing 1 mM EDTA, 10 mM divalent cation and the appropriate radioligand. The reaction is initiated by addition of membrane protein. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. Non-specific binding is determined in the presence of 20 1 µM of the corresponding non-radioactive prostanoid. Incubations are conducted for 60 min at room temperature or 30 °C and terminated by rapid filtration. Specific binding is calculated by subtracting non specific binding from total binding. The residual specific binding at each ligand concentration is calculated and expressed as a function of ligand concentration in order to construct sigmoidal concentration-
25 response curves for determination of ligand affinity.
30

Prostanoid receptor agonist and antagonist assays

Whole cell second messenger assays measuring stimulation (EP₂, EP₄, DP and IP in HEK 293(ebna) cells) or inhibition (EP₃ in human erythroleukemia

(HEL) cells) of intracellular cAMP accumulation or mobilization of intracellular calcium (EP₁, FP and TP in HEK 293(ebna) cells stably transfected with apo-aequorin) are performed to determine whether receptor ligands are agonists or antagonists. For cAMP assays, cells are harvested and resuspended in HBSS
5 containing 25 mM HEPES, pH 7.4. Incubations contain 100 µM RO-20174 (phosphodiesterase type IV inhibitor, available from Biomol) and, in the case of the EP₃ inhibition assay only, 15 µM forskolin to stimulate cAMP production. Samples are incubated at 37°C for 10 min, the reaction is terminated and cAMP levels are then measured. For calcium mobilization assays, cells are charged with the co-factors
10 reduced glutathione and coelenterazine, harvested and resuspended in Ham's F12 medium. Calcium mobilization is measured by monitoring luminescence provoked by calcium binding to the intracellular photoprotein aequorin. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. For agonists, second messenger responses are expressed as a function of ligand concentration and
15 both EC₅₀ values and the maximum response as compared to a prostanoid standard are calculated. For antagonists, the ability of a ligand to inhibit an agonist response is determined by Schild analysis and both K_B and slope values are calculated.

Rat Paw Edema Assay

20 The method is the same as described in Chan *et al* (J. Pharmacol. Exp. Ther. 274: 1531-1537, 1995).

LPS-Induced Pyrexia in Conscious Rats

25 The method is the same as described in Chan *et al* (J. Pharmacol. Exp. Ther. 274: 1531-1537, 1995).

LPS-Induced Pyrexia in Conscious Squirrel Monkeys

The method is the same as described in Chan *et al* (Eur. J. Pharmacol. 327: 221- 225, 1997).

30 Acute Inflammatory Hyperalgesia Induced by Carrageenan in Rats

The method is the same as described in Boyce *et al* (Neuropharmacology 33: 1609-1611, 1994).

Adjuvant-Induced Arthritis in Rats

Female Lewis rats (body weight ~146-170 g) were weighed, ear marked, and assigned to groups (a negative control group in which arthritis was not induced, a vehicle control group, a positive control group administered indomethacin at a total daily dose of 1 mg/kg and four groups administered with a test compound at total daily doses of 0.10-3.0 mg/kg) such that the body weights were equivalent within each group. Six groups of 10 rats each were injected into a hind paw with 0.5 mg of *Mycobacterium butyricum* in 0.1 mL of light mineral oil (adjuvant), and a negative control group of 10 rats was not injected with adjuvant. Body weights, contralateral paw volumes (determined by mercury displacement plethysmography) and lateral radiographs (obtained under Ketamine and Xylazine anesthesia) were determined before (day -1) and 21 days following adjuvant injection, and primary paw volumes were determined before (day -1) and on days 4 and 21 following adjuvant injection. The rats were anesthetized with an intramuscular injection of 0.03 - 0.1 mL of a combination of Ketamine (87 mg/kg) and Xylazine (13 mg/kg) for radiographs and injection of adjuvant. The radiographs were made of both hind paws on day 0 and day 21 using the Faxitron (45 kVp, 30 seconds) and Kodak X-OMAT TL film, and were developed in an automatic processor. Radiographs were evaluated for changes in the soft and hard tissues by an investigator who was blinded to experimental treatment.

The following radiographic changes were graded numerically according to severity: increased soft issue volume (0-4), narrowing or widening of joint spaces (0-5) subchondral erosion (0-3), periosteal reaction (0-4), osteolysis (0-4) subluxation (0-3), and degenerative joint changes (0-3). Specific criteria were used to establish the numerical grade of severity for each radiographic change. The maximum possible score per foot was 26. A test compound at total daily doses of 0.1, 0.3, 1, and 3 mg/kg/day, indomethacin at a total daily dose of 1 mg/kg/day, or vehicle (0.5% methocel in sterile water) are administered per os b.i.d. beginning post injection of adjuvant and continuing for 21 days. The compounds are prepared weekly, refrigerated in the dark until used, and vortex mixed immediately prior to administration.

EXAMPLES

The invention is illustrated in connection with the following non-limiting Examples. All the end products of the formula A were analyzed by NMR, TLC and mass spectrometry.

5 Intermediates were analyzed by NMR and TLC.
Most compounds were purified by flash chromatography on silica gel.
Recrystallization and/or swish (suspension in a solvent followed by filtration of the solid) with a solvent such as ether:hexane 1:1.
The course of reactions was followed by thin layer chromatography
10 (TLC) and reaction times are given for illustration only.
Temperatures are in degrees Celsius.

EXAMPLE 1**4-[3-[2-(PHENYLMETHOXY)PHENYL]-2-THIENYL]BENZOIC ACID**

15 2-Bromophenylbenzyl ether (3.5g, 13.3 mmol, prepared from 2-bromophenol following standard benzylation procedure) was reacted with thiophene 3-boronic acid (2.1g, 16.6 mmol, purchased from Lancaster), tetrakis(triphenylphosphine) palladium (770mg, 0.7 mmol) and 2M Na₂CO₃ (25 mL) in 1,2-dimethoxyethane (75 mL) at 90 °C for 24 hours. The mixture was cooled down
20 and a saturated solution of ammonium chloride and ethyl acetate were added. The separated aqueous layer was extracted with ethyl acetate (3 X 50 mL) and the combined organic layers were dried (MgSO₄ anh.), filtered and evaporated. Flash-chromatography of the residue (ethyl acetate-hexanes 1:10) yielded 3.5g of thiophene 3 (Scheme 1) which was selectively brominated at the 2 position according to the
25 following procedure: Thiophene 3 (2.4g, 9.0 mmol) was treated with N-bromosuccinimide (1.6g, 9.0 mmol) in THF (50 mL) containing 0.5 mL of water. The mixture was stirred at room temperature for 1.5 hours and water and diethyl ether were added. The separated aqueous layer was extracted with ether (3 X 50 mL) and the combined organic layers were dried (MgSO₄ anh.), filtered and evaporated.
30 Flash-chromatography of the residue (ethyl acetate-hexanes 1:10) yielded 3.1 g of the bromothiophene 4. The 2-bromo thiophene derivative 4 (3.1g, 9.0 mmol) was reacted with 4-carboxybenzenboronic acid (1.5g, 9.1 mmol), tetrakis(triphenylphosphine) palladium (520mg, 0.5 mmol) and 2M Na₂CO₃ (14 mL) in 1,2-dimethoxyethane (100 mL) at 90 °C for 24 hours. The mixture was cooled down and a saturated solution of

ammonium chloride and ethyl acetate were added. The separated aqueous layer was extracted with ethyl acetate (3 X 50 mL) and the combined organic layers were dried (MgSO_4 anh.), filtered and evaporated. Flash-chromatography of the residue (ethyl acetate-hexanes 1:10) yielded 1.9g of the title compound. ^1H nmr (400 MHz, CD_3COCD_3) δ ppm 7.87 (2H, d, $J = 11.5$ Hz), 7.58 (1H, d, $J = 5.0$ Hz), 7.35-7.09 (11H, m), 6.96 (1H, dt, $J = 10.0, 1.5$ Hz), 4.95 (2H, s). Elemental analysis calculated for $\text{C}_{24}\text{H}_{17}\text{SO}_3\text{Na} \cdot 1.5\text{H}_2\text{O}$: C, 66.20, H, 4.63, S, 7.36; found: C, 66.00, H, 4.27, S, 7.44.

10

EXAMPLE 2

4-[2-[2-(PHENYLMETHOXY)PHENYL]-3-THIENYL]BENZOIC ACID

A mixture of 3-bromothiophene (725mg, 7.7 mmol) (Scheme 2), carboethoxybenzeneboronic acid (1.1g, 5.9 mmol), tetrakis(triphenylphosphine) palladium (444mg, 0.4 mmol) and 2M Na_2CO_3 (9 mL) in 1,2-dimethoxyethane (60 mL) was heated at 90 °C for 24 hours. The mixture was cooled down and a saturated solution of ammonium chloride and ethyl acetate were added. The separated aqueous layer was extracted with ethyl acetate (3 X 50 mL) and the combined organic layers were dried (MgSO_4 anh.), filtered and evaporated. Flash-chromatography of the residue (ethyl acetate-hexanes 1:5) yielded 800 mg of thiophene derivative **9** which was converted to the bromide **10** using the conditions described above. The bromide **10** (1.3g, 4.0 mmol) was treated with the boronic acid **11** (1.3g, 6.0 mmol), tetrakis(triphenylphosphine) palladium (230mg, 0.2 mmol) and 2M Na_2CO_3 (1.2 mL) in 1,2-dimethoxyethane (25 mL) at 90 °C for 24 hours. The mixture was cooled down and a saturated solution of ammonium chloride and ethyl acetate were added. The separated aqueous layer was extracted with ethyl acetate (3 X 50 mL) and the combined organic layers were dried (MgSO_4 anh.), filtered and evaporated. Flash-chromatography of the residue (ethyl acetate-hexanes 1:10) yielded 700 mg of the ester which was then heated at 50 °C for 5 hours in a (1:1) mixture of dioxane-water (10 mL total) in the presence of lithium hydroxide (210mg). Work-up afforded 456 mg of the title compound. ^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.11 (2H, d, $J = 11.5$ Hz), 7.89 (2H, d, $J = 11.5$ Hz), 7.63 (2H, d, $J = 11.5$ Hz), 7.66 (1H, d, $J = 7.5$ Hz), 7.59 (1H, d, $J = 7.5$ Hz), 7.32, 7.22 (4H, 2m), 7.08 (2H, m), 6.97 (1H, dt, $J = 10.0, 1.5$ Hz), 4.95 (2H, s). Elemental analysis calculated for $\text{C}_{24}\text{H}_{17}\text{SO}_3\text{Na} \cdot 1.5\text{H}_2\text{O}$: C, 66.20, H, 4.63, S, 7.36; found:

35

EXAMPLE 3**2-(4-{3-[2-(PHENYLMETHOXY)PHENYL]-2-THIENYL}PHENYL)ACETIC ACID**

Prepared following the standard procedure described in example 1.

5 ^1H nmr (400 MHz, CD₃COCD₃) δ ppm 7.47 (1H, d, J = 7.5 Hz), 7.30-7.06 (14H, m), 6.91 (1H, t, J = 7.5 Hz), 4.95 (2H, s), 3.60 (2H, s).

EXAMPLE 4**(4-{3-[2-(PHENYLMETHOXY)PHENYL]-2-THIENYL}PHENYL)METHAN-1-OL**

10 To a solution of ethyl ester of example 1 (39 mg, 0.096 mmol) in THF (1.5 mL) at -78°C was added Et₃BHLi (1M in THF, 0.38 mL, 0.38 mmol) and the reaction was warmed to room temperature and stirred for 1 h.. The mixture was quenched with saturated NH₄Cl, diluted with Et₂O and washed successively with HCl 10%, aq. NaHCO₃ and brine. The ether layer was dried with anh. MgSO₄, 15 filtered and concentrated under reduced pressure to give a residue which was purified by flash chromatography (75% Hexanes/25% AcOEt) to provide the title compound (28.3 mg). ^1H nmr (400 MHz, acetone-d₆) δ ppm 7.45 (1H, d, J = 7.5 Hz), 7.32-7.05 (13H, m), 6.91 (1H, t, J = 7.5 Hz), 4.97 (2H, s), 4.60 (2H, d, J = 7.5 Hz), 3.95 (1H, t, J = 7.5 Hz).

20

EXAMPLE 5**2-(4-{3-[2-(PHENYLMETHOXY)PHENYL]-2-THIENYL}PHENYL)PROPAN-2-OL**

To a solution of ethyl ester of example 1 (34 mg, 0.084 mmol) in ether (1.5 mL) at -78°C was added MeMgBr (3M in ether, 0.11 mL, 0.33 mmol) and the reaction was warmed to room temperature and stirred for 1 h.. The mixture was quenched with saturated NH₄Cl, diluted with Et₂O and washed successively with HCl 10%, aq. NaHCO₃ and brine. The ether layer was dried with anh. MgSO₄, 25 filtered and concentrated under reduced pressure to give a residue which was purified by flash chromatography (75% Hexanes/25% AcOEt) to provide the title compound (25.6 mg). ^1H nmr (400 MHz, acetone-d₆) δ ppm 7.45-7.35 (3H, m), 7.39-7.05 (11H, m), 6.91 (1H, t, J = 7.5 Hz), 4.95 (2H, s), 3.95 (1H, bs), 1.47 (6H, s).

EXAMPLE 6

1-(4-[3-[2-(PHENYLMETHOXY)PHENYL]2-THIENYL)PHENYL)ETHAN-1-OL

To a solution of the alcohol of example 4 (200 mg, 0.536 mmol) in CH₂Cl₂ is added MnO₂ (467 mg, 5.36 mmol) and the mixture is stirred overnight.

5 The reaction is then filtered through a plug of celite and the crude mixture diluted in ether (5.0 mL) and cooled at -78°C. MeMgBr was then added (3M in ether, 0.22 mL, 0.66 mmol) and the reaction was warmed to room temperature and stirred for 1 h.. The mixture was quenched with saturated NH₄Cl, diluted with Et₂O and washed successively with HCl 10%, aq. NaHCO₃ and brine. The ether layer was dried with
10 anh. MgSO₄, filtered and concentrated under reduced pressure to give a residue which was separated in two and one part was purified by flash chromatography (70% Hexanes/30% AcOEt) to provide the title compound (19.4 mg). ¹H nmr (400 MHz, acetone-d₆) δ ppm 7.45 (1H, d, J = 7.5 Hz), 7.32-7.05 (13H, m), 6.91 (1H, t, J = 7.5 Hz), 4.97 (2H, s), 4.80 (1H, m) 4.12 (1H, d, J = 5.0 Hz), 3.95 (3H, d, J = 7.5 Hz).

15

EXAMPLE 7

4-(5-BROMO-3-[2-(PHENYLMETHOXY)PHENYL]2-THIENYL)BENZOIC ACID

To a solution of example 1 (0.48 g, 1.2 mmol) in THF/water (10/0.1 mL) was added N-bromosuccinimide (0.22 g, 1.2 mmol). The reaction was stirred overnight at room temperature. The mixture was then diluted with AcOEt and water, and the combined organic layer was washed with HCl 10%, NaHCO₃ (aq), brine, drier (anh. MgSO₄) and concentrated under reduced pressure to give a residue which was purified by flash chromatography (95% CH₂Cl₂/5% AcOEt) and crystallisation (CH₂Cl₂/Hexanes) to provide the title compound (0.16 g). ¹H nmr (400 MHz, acetone-d₆) δ ppm 7.76 (2H, d, J = 8.38 Hz), 7.23-7.11 (7H, m), 6.95 (2H, m), 6.87 (2H, d, J = 8.16 Hz), 6.71 (1H, t, J = 7.5 Hz), 4.90 (2H, s). Elemental analysis calculated for C₂₄H₁₆BrNaSO₃·4 H₂O : C, 51.53; H, 4.32, S, 5.73: found: C, 51.14; H, 3.76, S, 5.52.

30

EXAMPLE 8

4-[3-[5-CHLORO-2-(PHENYLMETHOXY)PHENYL]-2-THIENYL}
BENZOIC ACID

Prepared following the procedure described in example 1.

5 ^1H nmr (400 MHz, CD₃COCD₃) δ ppm 7.90 (2H, d, J = 11.5 Hz), 7.58 (1H, d, J = 5.0 Hz), 7.38-7.05 (11H, m), 4.94 (2H, s). Elemental analysis calculated for C₂₄H₁₆ClSO₃Na·H₂O: C, 62.54; H, 3.94, S, 6.96; found: C, 62.14; H, 3.82; S, 6.38.

EXAMPLE 9

10 3-[3-[5-CHLORO-2-(PHENYLMETHOXY)PHENYL]-2-THIENYL}
BENZOIC ACID

Prepared following the procedure described in example 1.

1H nmr (400 MHz, CD₃COCD₃) δ ppm 7.56-7.10 (14H, m), 5.13 (2H, s).

15 **EXAMPLE 10**

2-CHLORO-5-[3-[5-CHLORO-2-(PHENYLMETHOXY)PHENYL](2-
THIENYL)}BENZOIC ACID

Prepared following the procedure described in example 1.

1H nmr (400 MHz, acetone-d₆) δ ppm 7.80 (1H, d, J = 2.2 Hz), 7.57 (1H, d, J = 5.22 Hz), 7.40-7.20 (8H, m), 7.12-7.07 (3H, m), 4.92 (2H, s). Elemental analysis calculated for C₂₄H₁₅Cl₂NaSO₃·4 H₂O: C, 52.46; H, 4.22, S, 5.84; found: C, 52.05; H, 3.95, S, 5.54.

EXAMPLE 11

25 2-[2-(3-(2H-1,2,3,4-TETRAAZOL-5-YL)PHENYL)(3-THIENYL)]-4-CHLORO-1-
(PHENYLMETHOXY)BENZENE

To a solution of nitrile corresponding to the acid of example 9 (0.10 g, 0.26 mmol) in N-methyl pyrrolidine was added pyridine hydrochloride (0.30 g, 2.6 mmol) and sodium azide (0.34 g, 5.2 mmol). The reaction was stirred for 36 h. at 30 135°C, cooled down and then quenched by adding HCl 10%, diluted with AcOEt, washed with HCl 10%, brine, dried (anh. MgSO₄) and concentrated under reduced pressure to give a residue which was purified by flash-chromatography (80% CH₂Cl₂/19% AcOEt/1% AcOH), then crystallised (CH₂Cl₂/Hexanes to provide the title compound (0.05 g). 1H nmr (400 MHz, acetone-d₆) δ ppm 8.10 (1H, s), 8.01 (1H,

d, J = 7.5 Hz), 7.57 (1H, d, J = 5.22 Hz), 7.45 (1H, t, J = 7.5 Hz), 7.33 (1H, d, J = 7.5 Hz), 7.30 (1H, d, J = 7.5 Hz), 7.25-7.12 (5H, m), 7.07 (3H, m), 4.92 (2H, s).

EXAMPLE 12

5 5-[3-[5-CHLORO-2-(PHENYLMETHOXY)PHENYL](2-THIENYL)-2-METHOXYBENZOIC ACID

Prepared following the procedure described in example 1.

1H nmr (400 MHz, acetone-d₆) δ ppm 7.87 (1H, d, J = 2.30 Hz), 7.48 (1H, d, J = 5.22 Hz), 7.37 (1H, dd, J = 8.80, 2.70 Hz), 7.32-7.20 (4H, m), 7.18-7.05 (6H, m), 4.97 (2H, s), 3.95 (3H, s). Elemental analysis calculated for C₂₅H₁₈ClNaSO₄·3H₂O : C, 56.98; H, 4.59, S, 6.08: found: C, 56.86; H, 3.95, S, 5.50.

EXAMPLE 13

15 3-[3-[5-CHLORO-2-(PHENYLMETHOXY)PHENYL](2-THIENYL)-4-FLUOROBENZOIC ACID

Prepared following the procedure described in example 1.

1H nmr (400 MHz, acetone-d₆) δ ppm 8.00 (2H, m), 7.65 (1H, d, J = 5.20 Hz), 7.30-7.10 (9H, m), 7.03 (1H, d, J = 8.0 Hz), 4.95 (2H, s), 1.97 (3H, s). Elemental analysis calculated for C₂₄H₁₅ClNaSO₃·2 H₂O : C, 58.01; H, 3.85: found: C, 58.01; H, 3.40.

EXAMPLE 14

3-[3-[5-CHLORO-2-(PHENYLMETHOXY)PHENYL]-2-THIENYL]BENZAMIDE

To a solution of the acid of example 9 (0.45 g, 1.1 mmol) in pyridine (10 mL) at 0°C was added methanesulfonyl chloride (0.10 mL, 1.3 mmol) and the reaction was stirred for 1h. at 0°C. Ammonia was then introduced and the mixture was stirred for 1 h. at room temperature. The mixture was slowly quenched by adding HCl 10%, diluted with AcOEt, washed with HCl 10% , NaHCO₃ (aq), brine, dried (anh. MgSO₄) and concentrated under reduced pressure to give a residue which was purified by crystallisation (AcOEt /Hexanes) to provide the title compound (0.4 g). 1H nmr (400 MHz, acetone-d₆) δ ppm 7.92 (1H, s), 7.81 (1H, d, J = 3.57 Hz), 7.54 (1H, d, J = 5.17 Hz), 7.38 (1H, bs), 7.31-7.23 (6H, m), 7.18 (1H, d, J = 5.10 Hz) 7.15-7.02 (4H, m), 6.62 (1H,bs), 4.95 (2H, s). Elemental analysis calculated for C₂₄H₁₈ClNSO₂·H₂O : C, 65.82; H, 4.60; N, 3.20; S, 7.32; found: C, 66.21; H, 4.23; N, 3.00; S, 7.53.

EXAMPLE 15

2-(3-[5-CHLORO-2-(PHENYLMETHOXY)PHENYL]-2-THIENYL)PHENYL)ACETIC ACID

5 Prepared following the procedure described in example 1.

¹H nmr (400 MHz, acetone-d₆) δ ppm 7.49 (1H, d, J = 5.2 Hz), 7.29-7.05 (13H, m), 4.91 (2H, s), 3.52 (2H, s). Elemental analysis calculated for C₂₅H₁₈ClNaSO₃·1.5H₂O: C, 62.04; H, 4.37, S, 6.62; found: C, 61.63; H, 4.14, S, 6.37.

10

EXAMPLE 16

4-{3-[5-CHLORO-2-(PHENYLMETHOXY)PHENYL](2-THIENYL)}-2-METHYLBENZOIC ACID

Prepared following the procedure described in example 1.

¹H nmr (400 MHz, CD₃COCD₃) δ ppm 7.80 (1H, d, J = 10.5 Hz), 7.50 (1H, d, J = 7.0 Hz), 7.28-7.00 (11H, m), 4.88 (2H, s), 2.05 (3H, s). Elemental analysis calculated for C₂₅H₁₈ClSO₃Na·1.5H₂O: C, 62.05, H, 4.37, S, 6.63; found: C, 62.34, H, 4.00, S, 6.16.

20

EXAMPLE 17

4-(3-{2-[(2-CHLORO-4-FLUOROPHENYL)METHOXY]-5-NITROPHENYL}-2-THIENYL)BENZOIC ACID

Prepared following the procedure described in example 1.

¹H nmr (400 MHz, acetone-d₆) δ ppm 8.28 (1H, dd, J = 9.13, 2.88 Hz), 8.10 (1H, d, J = 2.87 Hz), 7.87 (2H, d, J = 8.52 Hz), 7.64 (1H, d, J = 5.20 Hz), 7.39-7.14 (6H, m), 7.05 (1H, dt, J = 8.44, 2.60 Hz), 5.14 (2H, s). Elemental analysis calculated for C₂₄H₁₄FCINaSO₅·2 H₂O : C, 53.19; H, 3.34; N, 2.58; S, 5.92; found: C, 52.71; H, 2.90; N, 2.52; S, 5.67.

30

EXAMPLE 18

(4-{3-[5-CHLORO-2-(PHENYLMETHOXY)PHENYL](2-THIENYL)}PHENYL)-N-(3-PYRIDYLMETHYL)FORMAMIDE

The benzoic acid of example 8 (900 mg, 2.2 mmol) was added at -78 °C to a mixture of EDCI (820 mg, 4.4 mmol) and 3-aminomethylpyridine (330 µL, 3.0 mmol) in dichloromethane (20 mL). The mixture was warmed to room temperature and stirred for 12 hours, and a 10% solution of sodium bicarbonate was

added. The separated aqueous layer was extracted with dichloromethane (3 X 50 mL) and the combined organic layers were dried (MgSO_4 anh.), filtered and evaporated. Flash-chromatography of the residue (ethyl acetate: dichloromethane, 3:7) yielded 450 mg of the title compound. ^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.60 (1H, br. s.), 8.46 (1H, m), 8.31 (1H, m), 7.82 (2H, d, J = 11.5 Hz), 7.77 (1H, d, J = 11.5 Hz), 7.56 (1H, d, J = 7.5 Hz), 7.31-7.16 (9H, m), 7.06 (3H, m), 4.94 (2H, s), 4.62 (2H, br. d). Elemental analysis calculated for $\text{C}_{30}\text{H}_{24}\text{ClN}_2\text{SO}_2\text{Na}\cdot\text{H}_2\text{O}$: C, , H, , S, ; found: C, , H, , S, .

10

EXAMPLE 19

[4-(3-[2-{(2-CHLORO-4-FLUOROPHENYL)METHOXY]-5-NITROPHENYL}(2-THIENYL))PHENYL]-N-(3-PYRIDYLMETHYL)FORMAMIDE

Prepared following the procedure described for example 18.

^1H nmr (400 MHz, acetone-d₆) δ ppm 8.78 (1H, s), 8.68 (1H, bs), 8.63 (1H, d, J = 3.8 Hz), 8.35 (1H, d, J = 8.16 Hz), 8.27 (1H, dd, J = 9.13, 2.90 Hz), 8.08 (1H, d, J = 2.86 Hz), 7.79 (3H, m), 7.62 (1H, d, J = 5.20 Hz), 7.37 (1H, d, J = 9.13 Hz), 7.27 (5H, m), 7.08 (1H, m), 5.13 (2H, s), 4.75 (2H, d, J = 5.71 Hz).

20

EXAMPLE 20

(4-{3-[5-CHLORO-2-(PHENYLMETHOXY)PHENYL}(2-THIENYL)}PHENYL)-N-(2-THIENYLSULFONYL)FORMAMIDE

The benzoic acid of example 8 (350 mg, 0.8 mmol) was added at room temperature to a mixture of EDCI (175 mg, 0.9 mmol), 4-dimethylaminopyridine (300 mg, 2.5 mmol) and 2-sulfonamidothiophene (156mg, 1.0 mmol) in dichloromethane (12 mL). The mixture was stirred for 12 hours at room temperature and a 1N solution of HCl was added. The separated aqueous layer was extracted with dichloromethane (3 X 50 mL) and the combined organic layers were dried (MgSO_4 anh.), filtered and evaporated. Flash-chromatography of the residue (ethyl acetate: dichloromethane, 3:7) was followed by trituration in dichloromethane:hexanes (1:10) yielded 290 mg of the title compound. ^1H nmr (400 MHz, CD_3COCD_3) δ ppm 7.99 (1H, dd, J = 5.5, 1.5 Hz), 7.91 (1H, m), 7.81 (2H, d, J = 11.5 Hz), 7.60 (1H, d, J = 7.5 Hz), 7.31 (2H, d, J = 10.0 Hz), 7.29 (1H, m), 7.20 (6H, m), 7.10 (1H, d, J = 11.5 Hz), 7.06 (2H, m), 4.91 (2H, s). Elemental analysis calculated for $\text{C}_{28}\text{H}_{19}\text{ClNS}_3\text{O}_4\text{Na}\cdot1.5\text{H}_2\text{O}$: C, 54.67, H, 3.61, S, 15.64, N, 2.28; found: C, 54.28, H, 3.24, S, 15.60, N, 2.29.

35

EXAMPLE 21

4-(3-{2-[(2,4-DIFLUOROPHENYL)METHOXY]-5-CHLOROPHENYL}(2-THIENYL))-3-METHYLBENZOIC ACID

Prepared following the procedure described in example 1.

5 ^1H nmr (400 MHz, acetone-d₆) δ ppm 7.77 (2H, m), 7.50 (2H,m), 7.29-7.17 (4H, m),
7.07 (2H, m), 6.93 (1H, d, J = 2.3 Hz), 5.09 (2H, s), 1.97 (3H, s). Elemental analysis
calculated for C₂₅H₁₆ClF₂NaSO₃·2.5 H₂O : C, 55.82; H, 3.93; S, 5.96 : found: C,
55.61; H, 3.41; S, 5.87.

10

EXAMPLE 22

4-(3-{5-CHLORO-2-[(4-FLUOROPHENYL)METHOXY]PHENYL}(2-THIENYL))-3-METHYLBENZOIC ACID

Prepared following the procedure described in example 1.

15 ^1H nmr (400 MHz, acetone-d₆) δ ppm 7.80 (2H, m), 7.60 (1H, d, J = 5.2 Hz), 7.35-
7.25 (4H, m), 7.20 (1H, dd, J = 7.5, 2.2 Hz), 7.12-7.02 (3H, m), 6.98 (1H, d, J = 2.2
Hz), 5.03 (2H, s), 2.05 (3H, s). Elemental analysis calculated for
C₂₅H₁₇ClFNaSO₃·1.5 H₂O : C, 59.82; H, 4.01: found: C, 59.74; H, 3.67.

20

EXAMPLE 23

4-[3-{5-CHLORO-2-(PHENYLMETHOXY)PHENYL}(2-THIENYL)-3-METHYLBENZOIC ACID

Prepared following the procedure described in example 1.

15 ^1H nmr (400 MHz, acetone-d₆) δ ppm 7.80 (2H, m), 7.58 (1H, d, J = 5.2 Hz), 7.35-
7.15 (8H, m), 7.04-6.98 (2H, m), 5.03 (2H, s), 2.05 (3H, s). Elemental analysis
calculated for C₂₅H₁₈ClNaSO₃·1 H₂O : C, 63.22; H, 4.24; S, 6.75 : found: C, 63.11;
H, 4.04; S, 6.62.

EXAMPLE 24

4-[4-[2-(PHENYLMETHOXY)PHENYL]-3-THIENYL]BENZOIC ACID

30 3,4-bromothiophene (920 μL , 7.7 mmol) was treated with **8** (500 mg,
2.6 mmol), tetrakis(triphenylphosphine) palladium (150 mg, 0.15 mmol) and 2M
Na₂CO₃ in 1,2-dimethoxyethane (25 mL) at 90 °C for 12 hours. The mixture was
cooled and a saturated solution of ammonium chloride and ethyl acetate were added.
The separated aqueous layer was extracted with ethyl acetate (3 X 50 mL) and the
combined organic layers were dried (MgSO₄ anh.), filtered and evaporated. Flash-

35

chromatography of the residue (ethyl acetate: hexanes, 1:8) yielded 420 mg of **15** which was then treated with boronic acid **11** following a procedure similar to those already described (*vide supra*) to provide **16**. Ethyl ester **16** (560 mg, 1.4 mmol) was then hydrolyzed with 1N lithium hydroxide (8 mL) in dioxane (16 mL) at 50 °C for 5 hours. The mixture was cooled down and a 1N solution of HCl and ethyl acetate were added. The separated aqueous layer was extracted with ethyl acetate (3 X 50 mL) and the combined organic layers were dried (MgSO_4 anh.), filtered and evaporated.

Flash-chromatography of the residue (dichloromethane: ethyl acetate: acetic acid, 95: 4: 1) provided the title compound. ^1H nmr (400 MHz, acetone-d₆) δ ppm 7.84 (2H, d, *J* = 8.1 Hz), 7.63 (1H, d, *J* = 3.2 Hz), 7.46 (1H, d, *J* = 3.1 Hz), 7.29-7.20 (7H, m), 6.99-6.93 (4H, m), 4.76 (2H, s). Elemental analysis calculated for $\text{C}_{30}\text{H}_{25}\text{N}_2\text{SClO}_2 \cdot 1 \text{ H}_2\text{O}$: C, 67.59; H, 4.49; found: C, 67.54; H, 4.33.

EXAMPLE 25

15 (4-[4-[2-(PHENYLMETHOXY)PHENYL](3-THIENYL)PHENYL]-N-(3-PYRIDYLMETHYL)FORMAMIDE

Prepared following the standard procedure described for example 18
 ^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.60 (1H, d, *J* = 1.7 Hz), 8.45 (1H, dd, *J* = 4.8, 1.6 Hz), 8.30 (1H, bs), 7.75 (3H, m), 7.60 (1H, d, *J* = 3.3 Hz), 7.45 (1H, d, *J* = 3.3 Hz), 7.23 (8H, m), 6.95 (4H, m), 4.77 (2H, s), 4.60 (2H, d, *J* = 6.1 Hz). Elemental analysis calculated for $\text{C}_{30}\text{H}_{25}\text{N}_2\text{SClO}_2 \cdot 0.5 \text{ H}_2\text{O}$: C, 69.02; H, 5.02; N, 5.37; S, 6.15 : found: C, 68.51; H, 5.06; N, 5.39; S, 6.62.

EXAMPLE 26

25 4-[3-(2-{{[4-(DIFLUOROMETHOXY)PHENYL]METHOXY}-5-CHLOROPHENYL}(2-THIENYL)]-3-METHYLBENZOIC ACID

Prepared following the standard procedure described in example 1
 ^1H nmr (400 MHz, CD_3COCD_3) δ ppm 7.82 (1H, s), 7.80 (1H, d, *J* = 11.5 Hz), 7.60 (1H, d, *J* = 7.5 Hz), 7.32 (4H, m), 7.20 (1H, dd, *J* = 11.5, 1.5 Hz), 7.18 (2H, m), 7.09 (1H, d, *J* = 11.5 Hz), 6.97 (1H, s), 5.06 (2H, s).

EXAMPLE 27

4-(3-{2-[(4-CARBOXYPHENYL)METHOXY]-5-CHLOROPHENYL}-2-THIENYL)BENZOIC ACID

Prepared following the standard procedure described in example 1
 5 ¹H nmr (400 MHz, CD₃COCD₃) δ ppm 7.88 (4H, t, J = 7.0 Hz), 7.62 (1H, d, J = 6.0 Hz), 7.31 (3H, m), 7.19 (4H, m), 7.10 (1H, d, J = 11.5 Hz), 5.04 (2H, s). Elemental analysis calculated for C₂₅H₁₅ClN₂SO₅Na·6H₂O: C, 48.67, H, 4.41 ; found: C, 49.00, H, 3.50.

10

EXAMPLE 28

3-(3-{2-[(4-CARBOXYPHENYL)METHOXY]-5-CHLOROPHENYL}-2-THIENYL)BENZOIC ACID

Prepared following the standard procedure described in example 1
 1 ¹H nmr (400 MHz, CD₃COCD₃) δ ppm 7.98 (1H, s.), 7.92 (3H, m), 7.59 (1H, d, J = 7.5 Hz), 7.45 (1H, m), 7.40 (1H, t, J = 10.0 Hz), 7.33 (1H, dd, J = 11.5. 1.5 Hz), 7.21 (4H, m), 7.09 (1H, d, J = 11.5 Hz), 5.01 (2H, s).

20

EXAMPLE 29

4-(3-{5-CHLORO-2-[(2-CHLORO-4-FLUOROPHENYL)METHOXY]PHENYL}(2-THIENYL))-3-METHYLBENZOIC ACID

25

Prepared following the standard procedure described in example 1
 1 ¹H nmr (400 MHz, CD₃COCD₃) δ ppm 7.79 (2H, m), 7.59 (1H, d, J = 5.2 Hz), 7.36-7.05 (7H, m), 7.00 (1H, d, J = 2.68 Hz), 5.07 (2H, s), 2.04 (3H, s). Elemental analysis calculated for C₂₅H₁₆Cl₂FNaSO₃·H₂O : C, 56.94; H, 3.44; S, 6.08 ; found: C, 57.18; H, 3.40; S, 6.33.

30

EXAMPLE 30

[4-(3-{5-CHLORO-2-[(2-CHLORO-4-FLUOROPHENYL)METHOXY]PHENYL}(2-THIENYL))-3-METHYLPHENYL]-N-(3-PYRIDYLMETHYL)FORMAMIDE

35


Prepared following the standard procedure described for example 18
 1 ¹H nmr (400 MHz, acetone-d₆) δ ppm 8.61 (1H, s), 8.42 (2H, m), 7.80-7.65 (3H, m),

7.53 (1H, d, J = 5.18 Hz), 7.45-7.00 (9H, m), 5.05 (2H, s), 4.60 (2H, d, J = 7.5 Hz), 2.00 (3H, s). Elemental analysis calculated for C₃₁H₂₄N₂Cl₃SFO₂·0.5H₂O: C,

59.77; H, 4.05; N, 4.50; S, 5.15 : found: C, 59.91; H, 4.22; N, 4.47; S, 5.38.

WHAT IS CLAIMED IS:

1. A compound represented by formula A



5

A

or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein:

y and z are independently 0-2, with the proviso that $y + z = 2$;

10 Ra is selected from the group consisting of:

1) heteroaryl, wherein heteroaryl is selected from the group

consisting of:

- a) furyl,
- b) diazinyl, triazinyl or tetrazinyl,
- c) imidazolyl,
- d) isoxazolyl,
- e) isothiazolyl,
- f) oxadiazolyl,
- g) oxazolyl,
- 15 h) pyrazolyl,
- i) pyrrolyl,
- j) thiadiazolyl,
- k) thiazoyl

20

- l) thienyl
- m) triazolyl and
- n) tetrazolyl, wherein heteroaryl is optionally substituted

with one or more substituents independently selected from R11 or C1-4alkyl,

- 5 2) -COR⁶,
- 3) -NR⁷R⁸,
- 4) -SO₂R⁹,
- 5) hydroxy,
- 6) C1-6alkoxy, optionally substituted with one or more

10 substituents independently selected from R11, and

- 7) C1-6alkyl, C2-6alkenyl or C3-6cycloalkyl, optionally

substituted with one or more substituents independently selected from R11, and
further substituted with 1-3 substituents independently selected from the group
consisting of:

- 15 (a) -COR⁶
- (b) -NR⁷R⁸,
- (c) -SO₂R⁹,
- (d) hydroxy,
- (e) C1-6alkoxy or haloC1-6alkoxy, and
- 20 (f) heteroaryl,

with the proviso that Ra is positioned on the phenyl ring to which it is bonded in a 1,3
or 1,4 relationship relative to the thienyl group represented in formula A;

each R1, R2, R3, R4 and R5 are independently selected from the group consisting of:

- 25 1) hydrogen,
- 2) halogen,
- 3) C1-6alkyl,
- 4) C1-6alkoxy,
- 5) C1-6alkylthio,

- 6) nitro,
- 7) carboxy and

8) CN, wherein items (3)-(5) above are optionally substituted with one or more substituents independently selected from R¹¹;

5

R⁶ is selected from the group consisting of hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy and NR⁷R⁸, wherein C₁₋₆alkyl or C₁₋₆alkoxy are optionally substituted with one or more substituents independently selected from R¹¹;

10 R⁷ and R⁸ are independently selected from the group consisting of:

- (1) hydrogen,
- (2) hydroxy,
- (3) SO₂R⁹
- (4) C₁₋₆alkyl,
- 15 (5) C₁₋₆alkoxy,
- (6) phenyl,
- (7) naphthyl,
- (8) furyl,
- (9) thienyl and

20 (10) pyridyl, wherein items (4)-(5) above are optionally substituted with one or more substituents independently selected from R¹¹, and items (6)-(10) above are optionally substituted with one or more substituents independently selected from R¹¹ or C₁₋₄alkyl,

25 R⁹ is selected from the group consisting of

- (1) hydroxy,
- (2) N(R¹⁰)₂,
- (3) C₁₋₆alkyl, optionally substituted with one or more substituents independently selected from R¹¹,

30 (4) phenyl,

- (5) naphthyl,
- (6) furyl,
- (7) thienyl and

(8) pyridyl, wherein items (4)-(8) above are optionally substituted with one or more substituents independently selected from R¹¹ or C₁₋₄alkyl;


R¹⁰ is hydrogen or C₁₋₆alkyl; and

R¹¹ is the group consisting of halogen, hydroxy, C₁₋₃alkoxy, nitro, N(R¹⁰)₂ and
5 pyridyl.

2. A compound in accordance with claim 1 wherein: R^a is selected from the group consisting of: heteroaryl, as originally defined, COR⁶, wherein R⁶ is as originally defined, C₁₋₆ alkyl and C₂₋₆ alkenyl, optionally substituted as originally defined, and SO₂R⁹ with R⁹ as originally defined.
10


3. A compound in accordance with claim 2 wherein R^a is selected from the group consisting of:

(1)




15

(2)




(3)




20


(4)




(5)



(6)




(7)




5


(8)



(9)




(10)




10

(11)






(12)





15

(13)







5




10



; and

(20)



4. A compound in accordance with claim 1 wherein 1-3 of R¹ and R² are selected from the group consisting of halo, C 1-4 alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio and NO₂.

5

5. A compound in accordance with claim 1 wherein each R⁴ and R⁵ independently represents a member selected from the group consisting of: H, halo, C₁₋₆ alkyl and C₁₋₆ alkoxy, said alkyl and alkoxy groups being optionally substituted as originally defined.

10

6. A compound in accordance with claim 1 wherein each R³ independently represents a member selected from the group consisting of: H and halo.

15

7. A compound in accordance with claim 1 wherein one of y and z represents 0 and the other represents 2.

20

8. A compound in accordance with claim 1 wherein:

R^a is selected from the group consisting of: heteroaryl, as originally defined, COR⁶, wherein R⁶ is as originally defined, C₁₋₆ alkyl and C₂₋₆ alkenyl,

optionally substituted as originally defined, and SO₂R⁹ with R⁹ as originally defined; 1-3 of R¹ and R² are selected from the group consisting of halo, C 1-4 alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio and NO₂;

each R⁴ and R⁵ independently represents a member selected from the group consisting of: H, halo, C₁₋₆ alkyl and C₁₋₆ alkoxy, said alkyl and alkoxy

groups being optionally substituted as originally defined;

each R³ independently represents a member selected from the group consisting of: H and halo;


and one of y and z represents 0 and the other represents 2.

30


9. A compound in accordance with claim 1 wherein:

R^a is selected from the group consisting of:


(1)



(2)




(3)




5

(4)




(5)




10

(6)




(7)




15


(8)




(9)



(10)




(11)




5

(12)




(13)







10

(14)





(15)





5



10

1-3 of R¹ and R² are selected from the group consisting of halo, C 1-4 alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio and NO₂;

each R⁴ and R⁵ independently represents a member selected from the group consisting of: H, halo, C₁₋₆ alkyl and C₁₋₆ alkoxy, said alkyl and alkoxy

15 groups being optionally substituted as originally defined;

each R³ independently represents a member selected from the group consisting of: H and halo;

and one of y and z represents 0 and the other represents 2.

10. A compound selected from the group consisting of:

- (a) 4-{3-[2-(Phenylmethoxy)phenyl]-2-thienyl}benzoic acid;
- (b) 4-{2-[2-(Phenylmethoxy)phenyl]-3-thienyl}benzoic acid;
- (c) 2-(4-{3-[2-(phenylmethoxy)phenyl]-2-thienyl}phenyl)acetic acid;
- 5 (d) (4-{3-[2-(phenylmethoxy)phenyl]-2-thienyl}phenyl)methan-1-ol;
- (e) 2-(4-{3-[2-(phenylmethoxy)phenyl]-2-thienyl}phenyl)propan-2-ol;
- 10 (f) 1-(4-{3-[2-(phenylmethoxy)phenyl]-2-thienyl}phenyl)ethan-1-ol;
- (g) 4-{5-bromo-3-[2-(phenylmethoxy)but-2-enyl]-2-thienyl}benzoic acid;
- (h) 4-{3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl}benzoic acid;
- 15 (i) 3-{3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl}benzoic acid;
- (j) 2-chloro-5-{3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)}benzoic acid;
- 20 (k) 2-[2-(3-(2H-1,2,3,4-tetraazol-5-yl)phenyl)(3-thienyl)]-4-chloro-1-(phenylmethoxy)benzene;
- (l) 5-{3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)}-2-methoxybenzoic acid;
- (m) 3-{3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)}-4-fluorobenzoic acid;
- 25 (o) 3-{3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl}benzamide;
- (p) 2-(3-{3-[5-chloro-2-(phenylmethoxy)phenyl]-2-thienyl}phenyl)acetic acid;
- (q) 4-{3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)}-2-methylbenzoic acid;
- 30 (r) 4-(3-{2-[(2-chloro-4-fluorophenyl)methoxy]-5-nitrophenyl}-2-thienyl)benzoic acid;
- (s) (4-{3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)}phenyl)-N-(3-pyridylmethyl)formamide;

(t) [4-(3-{2-[(2-chloro-4-fluorophenyl)methoxy]-5-nitrophenyl}(2-thienyl))phenyl]-N-(3-pyridylmethyl)formamide;

(u) (4-{3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)}phenyl)-N-(2-thienylsulfonyl)formamide;

5 (v) 4-(3-{2-[(2,4-difluorophenyl)methoxy]-5-chlorophenyl}(2-thienyl))-3-methylbenzoic acid;

(w) 4-(3-{5-chloro-2-[(4-fluorophenyl)methoxy]phenyl}(2-thienyl))-3-methylbenzoic acid;

(x) 4-{3-[5-chloro-2-(phenylmethoxy)phenyl](2-thienyl)}-3-methylbenzoic acid;

10 (y) 4-{4-[2-(phenylmethoxy)phenyl]-3-thienyl}benzoic acid;

(z) (4-{4-[2-(phenylmethoxy)phenyl](3-thienyl)}phenyl)-N-(3-pyridylmethyl)formamide;

(aa) 4-[3-(2-{[4-(difluoromethoxy)phenyl]methoxy}-5-chlorophenyl)(2-thienyl)]-3-methylbenzoic acid;

15 (ab) 4-(3-{2-[(4-carboxyphenyl)methoxy]-5-chlorophenyl}-2-thienyl)benzoic acid;







(ac) 3-(3-{2-[(4-carboxyphenyl)methoxy]-5-chlorophenyl}-2-thienyl)benzoic acid;







(ad) 4-(3-{5-chloro-2-[(2-chloro-4-fluorophenyl)methoxy]phenyl}(2-thienyl))-3-methylbenzoic acid; and







20 (ae) [4-(3-{5-chloro-2-[(2-chloro-4-fluorophenyl)methoxy]phenyl}(2-thienyl))-3-methylphenyl]-N-(3-pyridylmethyl)formamide,




25 or a pharmaceutically acceptable salt or ester thereof.




11. A compound selected from the group consisting of:



















































12. A pharmaceutical composition comprising a compound
5 according to any one of Claims 1 to 11 in combination with a pharmaceutically acceptable carrier.

13. A method of treating or preventing a prostaglandin mediated disease comprising administering to a mammalian patient in need of such treatment a compound according to Claim 1 in an amount which is effective for treating or preventing a prostaglandin mediated disease.
10

14. A method according to Claim 13 wherein the prostaglandin mediated disease is selected from the group consisting of:
15 (1) pain, fever or inflammation associated with rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal

5 pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases;

(2) cellular neoplastic transformations or metastatic tumor growth;

(3) diabetic retinopathy and tumor angiogenesis;

(4) prostanoid-induced smooth muscle contraction associated with dysmenorrhea, premature labor, asthma or eosinophil related disorders;

10 (5) Alzheimer's disease;

(6) glaucoma;

(7) bone loss;

(8) osteoporosis;

(9) promotion of bone formation;

15 (10) Paget's disease;

(11) cytoprotection in peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or other gastrointestinal lesions;

(12) GI bleeding and patients undergoing chemotherapy;

(13) coagulation disorders selected from hypoprothrombinemia,

20 haemophilia and other bleeding problems;

(14) kidney disease;

(15) thrombosis;

(16) occlusive vascular disease;

(17) presurgery; and

25 (18) anti-coagulation.

15. A method according to Claim 14 wherein the prostaglandin mediated disease is selected from the group consisting of: pain, fever or inflammation associated with rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases;.

16. A method according to Claim 15 wherein the prostaglandin mediated disease is pain, fever or inflammation associated with dysmenorrhea.

5 17. A method according to Claim 14, wherein the compound is co-administered with other agents or ingredients.

18. A method according to Claim 17 wherein the compound is co-administered with another agent or ingredient selected from the group consisting of:

10 (1) an analgesic selected from acetaminophen, phenacetin, aspirin, a narcotic;

(2) a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug or a conventional nonsteroidal anti-inflammatory drug;

(3) caffeine;

15 (4) an H₂-antagonist;

(5) aluminum or magnesium hydroxide;

(6) simethicone;

(7) a decongestant selected from phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline,

20 xylometazoline, propylhexedrine, or levo-desoxyephedrine;

(8) an antitussive selected from codeine, hydrocodone, caramiphen, carbetapentane and dextromethorphan;

(9) another prostaglandin ligand selected from misoprostol, enprostil, rioprostil, ornoprostol and rosaproston; a diuretic; and

25 (10) a sedating or non-sedating antihistamine.

19. A method according to Claim 17 wherein the compound is co-administered with a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug or a conventional nonsteroidal anti-inflammatory drug.

30 20. A method according to Claim 17 wherein the compound is co-administered with a conventional nonsteroidal anti-inflammatory drug selected from the group consisting of: aspirin, ibuprofen, naproxen, and ketoprofen.

21. A method according to Claim 19 wherein the compound is co-administered with a cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug selected from rofecoxib and celecoxib.

5 22. An E-type prostaglandin antagonist pharmaceutical composition comprising an acceptable, antagonistic amount of a compound of formula A, as defined in any one of Claims 1 to 9, or a pharmaceutically acceptable salt, hydrate or ester thereof, in association with a pharmaceutically acceptable carrier.

10 23. A compound, salt or ester of Claim 10 for use in treating or preventing a prostaglandin mediated disease.

 24. Use of a compound of Claim 11 in the manufacture of a medicament for treating or preventing a prostaglandin mediated disease.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number
WO 01/19814 A3

(51) International Patent Classification⁷: **C07D 333/24, A61K 31/381, 31/44, A61P 19/02, 29/00, C07D 333/16, 333/28, 409/10, 409/12, 333/34**

(74) Agents: MURPHY, Kevin, P. et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).

(21) International Application Number: **PCT/CA00/01059**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date:
13 September 2000 (13.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/153,899 14 September 1999 (14.09.1999) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA).

Published:

— *with international search report*


(72) Inventors; and
(75) Inventors/Applicants (*for US only*): **LACOMBE, Patrick [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). LABELLE, Marc [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). RUEL, Rejean [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA).**

(88) Date of publication of the international search report:
9 August 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

WO 01/19814 A3



(57) Abstract: This invention encompasses the novel compounds of formula (A), which are useful in the treatment of prostaglandin mediated diseases, or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses certain pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases comprising the use of compounds of formula (A).

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01059

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07D333/24	A61K31/381	A61K31/44	A61P19/02	A61P29/00
	C07D333/16	C07D333/28	C07D409/10	C07D409/12	C07D333/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 03380 A (ZENECA LTD ;BREULT GLORIA ANNE (GB); OLDFIELD JOHN (GB); TUCKER H) 8 February 1996 (1996-02-08) cited in the application page 30 -page 32 ----	1, 12, 13, 22-24
P, X	WO 00 20371 A (LACHANCE NICHOLAS ;BELLEY MICHEL (CA); LI CHUN (CA); GALLANT MICHE) 13 April 2000 (2000-04-13) claims 1-27 -----	1-24

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

23 February 2001

Date of mailing of the international search report

06/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Bader, K

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/01059

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9603380	A	08-02-1996	AT 196898 T AU 688541 B AU 2988395 A BG 101259 A BR 9508335 A CA 2192088 A CZ 9700220 A DE 69519099 D EP 0773930 A ES 2150577 T FI 970261 A HU 76606 A JP 10503487 T NO 970314 A NZ 289905 A PL 318283 A SK 10197 A US 5843942 A ZA 9506149 A	15-10-2000 12-03-1998 22-02-1996 31-03-1998 30-09-1997 08-02-1996 11-06-1997 16-11-2000 21-05-1997 01-12-2000 22-01-1997 28-10-1997 31-03-1998 13-03-1997 25-11-1998 09-06-1997 06-08-1997 01-12-1998 07-02-1996
WO 0020371	A	13-04-2000	AU 6072999 A	26-04-2000